Letter by Adabag et al Regarding Article, “Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Elming et al1 report that the efficacy of primary prevention implantable cardioverter-defibrillator (ICD) therapy is diminished among older participants of the DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality), which randomized patients with nonischemic cardiomyopathy to ICD versus optimal medical therapy.2 In this secondary data analysis of the DANISH trial, ICD implantation was associated with a statistically significant improvement in survival among patients ≤70 years of age but not in those >70 years of age. This area of study is important because …